 DURHAM, N.C.--BUSINESS WIRE--- DTIL ASH21--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, Decemb 